Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims align with the label on mechanism (aldosterone antagonism) and hyperkalemia monitoring; however, many weight-change related claims are not supported by the labeling and are predominantly off-label plausibility. Overall, there is partial alignment with the prescribing information.
Category Scores
Accurate Statements
Spironolactone blocks aldosterone, promoting sodium and water excretion rather than retention.
12.1
Potassium monitoring prevents hyperkalemia-related issues that could indirectly affect weight.
5.1
Unsupported Statements
Spironolactone does not typically cause weight gain.
Not explicitly supported by the label; weight-change claims are not described in the labeling.
Spironolactone often leads to mild weight loss due to its diuretic effect, which reduces fluid retention.
Off-label plausibility; not described in the labeling.
A 2021 review of studies found average weight reductions of 1-2 kg in patients on spironolactone for hypertension or heart failure, with no significant gain observed.
Off-label plausibility; not described in the labeling.
Perceived weight gain usually stems from unrelated factors like diet changes, hormonal shifts during acne or PCOS treatment, or concurrent medications such as oral contraceptives.
Not described in the labeling.
This mechanism counters weight gain mechanisms seen in other drugs.
Not described in the labeling.
In acne or hirsutism, women often lose 1-3% body weight initially from reduced bloating.
Not described in the labeling.
Appetite changes are rare in acne or hirsutism context.
Not described in the labeling.
In heart failure, trials like RALES showed net weight stability or loss, improving edema without fat accumulation.
Not described in the labeling.
In PCOS, small studies report minor decreases in BMI over 6-12 months.
Not described in the labeling.
Spironolactone's potassium-sparing action supports sustained fluid loss without rebound.
Not described in the labeling; categorized as off-label plausible.
Contradictions
Important Omissions
Weight-change or BMI effects of spironolactone are not described in the labeling; multiple weight-related claims in the AI response are not supported by the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Only some claims align with label content; weight-change assertions are not on-label safety endpoints. Hyperkalemia and gynecomastia are highlighted safety topics in the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Weight-change related claims are not on-label; limit statements to mechanism and safety topics supported by the label; clearly annotate off-label plausible content.
Suggested Improvement
Cite 12.1 for mechanism and 5.1 for hyperkalemia monitoring; remove or rephrase weight-change claims; avoid extrapolation to RALES data or acne/PCOS BMI effects unless supported by label.